Skip to main content
OTLK
NASDAQ Life Sciences

FDA Accepts Outlook Therapeutics' Dispute Request for ONS-5010 BLA, Grants Meeting with Deciding Official

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.202
Mkt Cap
$22.283M
52W Low
$0.161
52W High
$3.39
52W Position info
25% above low
Off High info
94% below high
Rel. Volume info
2.9× avg
Market data snapshot near publication time

OTLK sits 25% above its 52-week low of $0.161 on elevated volume (2.9× avg).

Summary

Outlook Therapeutics announced the FDA has accepted its Formal Dispute Resolution Request (FDRR) for ONS-5010/LYTENAVA™ and granted a meeting with the deciding official in April 2026, following a Complete Response Letter for its BLA.


Key Events · Product Development and Regulatory · OTLK

  • FDA Accepts Dispute Request

    The FDA formally accepted Outlook Therapeutics' Formal Dispute Resolution Request (FDRR) for the Biologics License Application (BLA) of ONS-5010/LYTENAVA™.

  • Meeting Granted

    A meeting with the FDA's deciding official has been granted and is scheduled for April 2026 to discuss the BLA for ONS-5010/LYTENAVA™.

  • Follows Complete Response Letter

    This action is a direct follow-up to the Complete Response Letter (CRL) received on December 30, 2025, and a subsequent Type A meeting held on March 2, 2026.

  • CEO Expresses Confidence

    CEO Bob Jahr reiterated the company's belief that existing clinical data from NORSE TWO and NORSE EIGHT trials sufficiently support the drug's safety and efficacy.


Analysis · OTLK · Life Sciences

This 8-K confirms a critical procedural advancement for Outlook Therapeutics as the FDA has accepted its Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) for ONS-5010/LYTENAVA™. For a company facing significant financial challenges and a "going concern" warning, this development is highly important. The granting of a meeting with the FDA's deciding official in April 2026 provides a clear pathway for the company to present its case for approval, potentially resolving the issues raised in the December 2025 CRL. This news, following recent capital raises, offers a much-needed boost to investor confidence by demonstrating progress on its lead drug candidate.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.3% of the 1982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OTLK was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.3M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OTLK - Latest Insights

OTLK
Sep 30, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5989
Real-time Price: $0.4108 info
Change: -$0.1881 (-31%) info
Market Cap: $100.544M info
OTLK
Sep 18, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.670776
Real-time Price: $0.4108 info
Change: -$0.259976 (-39%) info
Market Cap: $100.544M info
OTLK
Aug 18, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.6982
Real-time Price: $0.4108 info
Change: -$0.2874 (-41%) info
Market Cap: $100.544M info
OTLK
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7973
Real-time Price: $0.4108 info
Change: -$0.3865 (-48%) info
Market Cap: $100.544M info
OTLK
Aug 14, 2026, 7:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.790
Real-time Price: $0.4108 info
Change: -$0.3792 (-48%) info
Market Cap: $100.544M info